GSK's Vaccine Sales Decline Dims Profit Outlook Despite Strong Earnings

GlaxoSmithKline (GSK), the prominent British pharmaceutical giant, has reported a noticeable drop in its vaccine sales, which has raised concerns over future profitability. Despite achieving strong profits in the third quarter, the company’s reduced sales in the vaccines sector are overshadowing these positive financial results, signaling potential challenges ahead for one of its key revenue streams.

Continue reading